Aldeyra Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
36.3%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$1.3Mnext fiscal year
FY EPS (est.)
-$0.30next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly70MTarget: Sufficient to fund operations into 2028
Reproxalap Clinical Efficacy Trials (Totality of Evidence) Annually5.0Target: 9 (Total trials submitted in NDA)
Watch Items
- Type A Meeting with the FDA regarding Reproxalap Dry Eye Disease NDATrigger: Meeting scheduled or completed in Q2 2026Action: Evaluate FDA feedback on the totality of evidence and determine if an appeal to the Office of New Drugs or a specific path to approval is required without new clinical trials.
- AbbVie Exclusive Option Agreement on ReproxalapTrigger: Expiration within 10 business days of potential FDA approvalAction: Monitor if AbbVie exercises its option to co-develop and commercialize reproxalap in the U.S., which would trigger a $100 million upfront payment (less option fees).
- ADX-2191 Phase 3 Trial Initiation in Primary Vitreoretinal LymphomaTrigger: Initiation expected in H1 2026Action: Track patient enrollment and clinical progress under the Special Protocol Assessment (SPA) agreed with the FDA.
Research as of 20 Jun 2026